Merck KGaA Stock

If you see news about the pharmaceutical industry today and it isn't directly about GLP-1 weight loss drugs, it's likely to include at least a mention of this new class of medications. GLP-1 drugs

After lagging the market over the past couple of years, Merck (NYSE: MRK) has experienced a slight rebound in the last month, thanks to several positive developments. The stock has increased by 20%

Merck (NYSE: MRK) has taken its shareholders on a wild ride of late -- from last March's record high of more than $130 to this May's low near $76 back to its current price of just a little more than

Are things finally looking up for Merck (NYSE: MRK)? After being mostly southbound for the better part of the last two years, the pharmaceutical giant is showing signs of life. Over the past month

Over the past 18 months, Merck (NYSE: MRK) shares have been mostly southbound as the drugmaker encountered several headwinds. Its vaccine business isn't performing as well as expected, resulting in

Over the past two years, Merck (NYSE: MRK) has faced several challenges, resulting in a decline in the company's share price. Even worse, the pharmaceutical giant could face more issues ahead

Drug giant Eli Lilly (NYSE: LLY) now has the best-selling drug on the planet. It's a GLP-1 dual receptor agonist called tirzepatide, which Lilly sells as Mounjaro for treating type 2 diabetes and

All things considered, broader equities have performed pretty well in 2025, with the S&P 500 up 14% since the beginning of the year. It seems so long ago that the index flirted with bear-market

Eli Lilly (NYSE: LLY) manufactures a drug called tirzepatide, a GLP-1 dual receptor agonist, which it sells as Mounjaro for treating type 2 diabetes and Zepbound for weight loss. Tirzepatide became

The stock for pharmaceutical giant Merck (NYSE: MRK) was trading down more than 3% Monday morning. That's a big drop in just a few hours to start the week.

So, what's going on?

It might have to do

If you are looking for a healthcare stock to add to your portfolio as October draws to a close, consider Intuitive Surgical (NASDAQ: ISRG), Merck (NYSE: MRK), and Johnson & Johnson (NYSE: JNJ). Each

The market is forward-looking, but investors who earn better-than-average returns often look even further into the future and identify opportunities that are currently being overlooked. That means

Turning $10,000 into $50,000 in about five years would require a compound annual growth rate (CAGR) of almost 38%. That's an extremely tough task for any corporation, but can Merck (NYSE: MRK), a

If you are in your 20's you likely have more than four decades ahead of you to invest before hitting retirement. Some might suggest that now is the time to take an aggressive investment stance, but

The S&P 500 has a miserly yield of 1.2%. The average healthcare stock's yield is about 1.8%. Compared to that, Merck's (NYSE: MRK) roughly 4% yield is highly attractive. And LTC Properties' (NYSE:

If you are looking at healthcare stocks for dividend ideas in August, don't get too caught up on the sector's low 1.8% dividend yield. You can do much better than that without having to take on huge

The S&P 500 (SNPINDEX: ^GSPC) is offering investors a tiny yield of just 1.2% today. If you think you are being starved of dividend income, well, that's because you are. But you can do much better

On Tuesday, Merck (NYSE: MRK) wasn't one of the better-performing pharmaceutical stocks. In contrast to certain peers, the company's share price declined following the release of second-quarter

Merck (NYSE:MRK), a leading developer of prescription medicines, vaccines, and animal health products, released its second-quarter 2025 results on July 29, 2025. The most notable news was a beat on

Healthcare stocks aren't exactly known for offering large yields, with the average healthcare stock at just 1.8% or so. You can do better than that and get reliable dividend stocks while you are at

Merck (NYSE: MRK), a leading pharmaceutical company, generates consistent revenue and profits. However, the stock has been under pressure over the past year due to its reliance on Keytruda, its

One of the biggest concerns with healthcare giant Merck (NYSE: MRK) is its dependence on top-selling cancer drug Keytruda. While it has been a beast for the business over the years, generating